Sensorion Announces Positive Data from Audiogene SENS-501 Clinical Trial
Sensorion’s Phase 1/2 Audiogene trial of the gene therapy SENS-501 for infants and toddlers with OTOF-related congenital deafness shows promising early safety and hearing improvement data, particularly in one patient, with a higher dose cohort now underway.